← All trials
NCT06430905
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2024
- Primary completion
- Nov 30, 2025
- Completion date
- Nov 30, 2025
- First posted
- May 28, 2024
- Last posted
- Oct 18, 2024
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hookipa BiotechLead sponsor
- Hookipa BiotechOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.